RxDoctor Payments Data

Richard Seeger, MD

Ophthalmology · Webster, NYNPI 1083681001

Payments from drug & device makers

$867in general payments, 2019–2025

Across 14 payments — averaging $61.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$254
  • NEW World Medical,inc.$177
  • Amgen$164
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$125
  • Sight Sciences, Inc.$116
  • Johnson & Johnson Surgical Vision, Inc.$31

What the payments were for

  • Food & beverage$867100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$867 in reported general payments places this provider in the 45th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$144,967
Medicare patients
276
Services billed
894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate171$73,766
LumiganBimatoprost126$66,781
VyzultaLatanoprostene Bunod142$36,774
RocklatanNetarsudil Mesylat/Latanoprost77$29,897
RestasisCyclosporine18$29,054
Cyclosporine30$22,029
Prednisolone Acetate371$15,750
Brimonidine Tartrate311$14,504
Latanoprost1,280$14,367
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol55$12,149
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat467$9,426
Dorzolamide-TimololDorzolamide/Timolol/Pf56$8,663
Alphagan PBrimonidine Tartrate14$8,036
Ketorolac Tromethamine329$4,580
Timolol Maleate371$3,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$254$103,870158 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$125$2,31311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Webster

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →